GlassScriptPhysician profile
Naveed Salahuddin
NPI 1003860560
$8,493.08
in general payments reported to CMS, 2019-2025
29 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $514 · 2021: $344 · 2022: $1,161 · 2023: $1,861 · 2024: $1,493 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,103 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,103.26 |
| Education | $270.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,673.33 | 2019-2025 | Evenity, Prolia, Enbrel |
| Janssen Biotech, INC. | $1,334.84 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,202.98 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $942.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $498.45 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $455.53 | 2019-2025 | |
| Horizon Therapeutics Plc | $410.57 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $308.32 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $264.17 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $208.03 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.52 | 2019-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $151.79 | 2019-2025 | Orencia |
| Ucb, INC. | $145.30 | 2021-2025 | Cimzia, Bimzelx |
| Organon LLC | $116.31 | 2022-2024 | Renflexis, Hadlima |
| Sandoz INC. | $106.75 | 2023-2025 | Jubbonti, Hyrimoz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $93.19 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $46.90 | 2023 | Idacio |
| Idorsia Pharmaceuticals US INC | $46.53 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $34.81 | 2019 | |
| Zyla Life Sciences, INC. | $34.46 | 2019 | |
| Merck Sharp & Dohme LLC | $33.02 | 2019-2020 | |
| Hospira, INC. | $31.65 | 2024-2025 | |
| Lilly USA, LLC | $28.58 | 2019-2024 | Taltz, Zepbound |
| Mylan Institutional INC. | $27.86 | 2023 | Hulio |
| Antares Pharma, INC. | $27.66 | 2019-2020 | |
| Gilead Sciences, INC. | $25.69 | 2019-2020 | |
| Radius Health, INC. | $24.85 | 2020 | |
| Tonix Medicines, INC. | $22.19 | 2025 | Tonmya |
| Alexion Pharmaceuticals, INC. | $19.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Salahuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.